The structure and substrate specificity of human Cdk12/Cyclin K
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
Phosphorylation of the RNA polymerase II C-terminal domain (CTD) by cyclin-dependent kinases is important for productive transcription. Here we determine the crystal structure of Cdk12/CycK and analyse its requirements for substrate recognition. Active Cdk12/CycK is arranged in an open conformation similar to that of Cdk9/CycT but different from those of cell cycle kinases. Cdk12 contains a C-terminal extension that folds onto the N- and C-terminal lobes thereby contacting the ATP ribose. The interaction is mediated by an HE motif followed by a polybasic cluster that is conserved in transcriptional CDKs. Cdk12/CycK showed the highest activity on a CTD substrate prephosphorylated at position Ser7, whereas the common Lys7 substitution was not recognized. Flavopiridol is most potent towards Cdk12 but was still 10-fold more potent towards Cdk9. T-loop phosphorylation of Cdk12 required coexpression with a Cdk-activating kinase. These results suggest the regulation of Pol II elongation by a relay of transcriptionally active CTD kinases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Cdk12 activity on the CTD requires Ser7 prephosphorylation. (a) Design of CTD substrate peptides used for kinetic and ESI-MS analyses. Peptides contained three consensus hepta-repeats with either no modification (cons. CTD[3]) or with phosphorylation marks continuously set at one residue of the heptad sequence as shown for Ser7 (pS7-CTD[3]). The same design principle was used for CTD peptides phosphorylated at Tyr1 (pY1-CTD[3]), Ser2 (pS2-CTD[3]), Thr4 (pT4-CTD[3]) and Ser5 (pS5-CTD[3]) or a peptide that contained a lysine at position 7 (K7-CTD[3]). (b) Activity of Cdk12/CycK for various CTD substrates. Of the seven peptides tested, Cdk12 showed the highest activity for continuous Ser7 prephosphorylation. Minor activities were detected for Ser2 and Thr4 prephosphorylated peptides. Remarkably, no activity was seen for cons. CTD[3] or the K7-peptide, which is in contrast to P-TEFb. In addition, Cdk12 exhibited no activity on the pSer5 peptide. (c) ESI-MS analyses of CTD peptides before and after 4 h of incubation with 2 μM Cdk12/CycK. Whereas no phosphorylation occurred for the consensus peptide, the pS7-CTD[3] substrate got readily phosphorylated up to three times. (d) Time course of Cdk12/CycK mediated CTD phosphorylation. The prephosphorylated Ser7 peptide got phosphorylated over time to saturation, while the non-phosphorylated peptide showed low susceptibility as a Cdk12 substrate. Data in panels b and d are the mean±s.d. of three independent experiments.](https://figures.cochat.ai/paper-figures/10d663b65180482a83bae3bf104eeec2/the-structure-and-substrate-specificity-of-human-cdk12-cyclin-k-figure-3.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CR8 is a pleiotropic CDK inhibitor reported to bind CDK1/2/3/5/7/9/126,19”
From The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K (2020) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, we identified cyclin-dependent kinase 12 (CDK12), which is a known target of CR819 and whose activity depends on the interaction with cycK20, as a crucial component for CR8-induced cycKeGFP destabilisation (Fig. 1g, Extended Data Fig. 2h–k).”
From The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K (2020) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CDK12 and CDK13 are two structurally similar kinases that has the ability to phosphorylate serine 2 of the POLII CTD heptad repeats (Bösken et al., 2014; Dixon-Clarke et al., 2015; Greifenberg et al., 2016).”
From Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation (2020) · cites this paper as Bösken et al., 2014
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The density for this region could only be tentatively assigned, likely due to the presence of multiple conformations, but the CDK12 C-terminal tail clearly engages with DDB1 and assumes a conformation different from those seen in isolated CDK12-cycK structures (Extended Data Fig. 6a, b, d)19,21.”
From The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K (2020) · cites this paper as [19]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
REFMAC 5 for the refinement of macromolecular crystal structures
Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., Winn, M. D., Long, F., & Vagin, A. A. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444911001314 · Cited by 8,317
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
PHENIX: a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2012) · International Tables for Crystallography · doi:10.1107/97809553602060000865 · Cited by 7,334
The Conformational Plasticity of Protein Kinases
Huse, M., & Kuriyan, J. (2002) · Cell · doi:10.1016/s0092-8674(02)00741-9 · Cited by 1,752
Transcriptional Regulation and Its Misregulation in Disease
Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.02.014 · Cited by 1,620
Diverse somatic mutation patterns and pathway alterations in human cancers
Kan, Z., Jaiswal, B. S., Stinson, J., Janakiraman, V., Bhatt, D., Stern, H. M., Yue, P., Haverty, P. M., Bourgon, R., Zheng, J., et al. (2010) · Nature · doi:10.1038/nature09208 · Cited by 1,027
Cited by
The code and beyond: transcription regulation by the RNA polymerase II carboxy-terminal domain
Harlen, K. M., & Churchman, L. S. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.10 · Cited by 499
Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor
Christensen, C. L., Kwiatkowski, N., Abraham, B. J., Carretero, J., Al-Shahrour, F., Zhang, T., Chipumuro, E., Herter-Sprie, G. S., Akbay, E. A., Altabef, A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.019 · Cited by 439
“Both Flavopiridol and THZ1 have been shown to cross react with CDK12/13 at higher concentrations (Bosken et al., 2014; Kwiatkowski et al., 2014), therefore this shared pharmacology may also impact the transcriptional and phenotypic response of SCLC to these inhibitors.”
The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K
Słabicki, M., Kozicka, Z., Petzold, G., Li, Y.-D., Manojkumar, M., Bunker, R. D., Donovan, K. A., Sievers, Q. L., Koeppel, J., Suchyta, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2374-x · Cited by 433
Inhibitors of cyclin-dependent kinases as cancer therapeutics.
Whittaker, S. R., Mallinger, A., Workman, P., & Clarke, P. A. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.008 · Cited by 384
“However, knockout or chemical inhibition experiments have had, at best, modest effects on global CTD phosphorylation, which can be interpreted as CDK12 either having no importance in human CTD Ser2 phosphorylation or having functional redundancy with CDK13 or other Ser2 kinases (Bosken et al., 2014; Bartkowiak, Yan, &…”
Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors
Zhang, T., Kwiatkowski, N., Olson, C. M., Dixon-Clarke, S. E., Abraham, B. J., Greifenberg, A. K., Ficarro, S. B., Elkins, J. M., Liang, Y., Hannett, N. M., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2166 · Cited by 374
Self-citationCyclin-dependent protein kinases and cell cycle regulation in biology and disease
Pellarin, I., Dall’Acqua, A., Favero, A., Segatto, I., Rossi, V., Crestan, N., Karimbayli, J., Belletti, B., & Baldassarre, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02080-z · Cited by 304
Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy
Chou, J., Quigley, D. A., Robinson, T. M., Feng, F. Y., & Ashworth, A. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0528 · Cited by 287
“Structural studies of CDK12 and CDK13 have demonstrated that the amino-terminal lobe of the CDK12 kinase domain interfaces with the cyclin box of cyclin K, creating CDK12:cyclin K heterodimers, which then further dimerize (35).”
BackgroundJohnson, S. F., Cruz, C., Greifenberg, A. K., Dust, S., Stover, D. G., Chi, D., Primack, B., Cao, S., Bernhardy, A. J., Coulson, R., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.10.077 · Cited by 291
Self-citationKrajewska, M., Dries, R., Grassetti, A. V., Dust, S., Gao, Y., Huang, H., Sharma, B., Day, D. S., Kwiatkowski, N., Pomaville, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09703-y · Cited by 281
Self-citationStructural insights into the functional diversity of the CDK–cyclin family
Wood, D. J., & Endicott, J. A. (2018) · Open Biology · doi:10.1098/rsob.180112 · Cited by 260
Brd4 activates P-TEFb for RNA polymerase II CTD phosphorylation
Itzen, F., Greifenberg, A. K., Bösken, C. A., & Geyer, M. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku449 · Cited by 236
Self-citationThe pol II CTD: new twists in the tail
Zaborowska, J., Egloff, S., & Murphy, S. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3285 · Cited by 226
Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation
Lv, L., Chen, P., Cao, L., Li, Y., Zeng, Z., Cui, Y., Wu, Q., Li, J., Wang, J.-H., Dong, M.-Q., et al. (2020) · eLife · doi:10.7554/elife.59994 · Cited by 215
Düster, R., Kaltheuner, I. H., Schmitz, M., & Geyer, M. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100260 · Cited by 204
Self-citationCDK7 inhibitors as anticancer drugs
Sava, G. P., Fan, H., Coombes, R. C., Buluwela, L., & Ali, S. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09885-8 · Cited by 200
“In vitro, CDK12 can phosphorylate Ser2, Ser5 and Ser7 [54], whereas CDK13 can phosphorylate Ser2 and Ser5 [55].”
BackgroundLiang, K., Gao, X., Gilmore, J. M., Florens, L., Washburn, M. P., Smith, E., & Shilatifard, A. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.01426-14 · Cited by 192
“These results are consistent with recent studies that observed low levels of CTD phosphorylation implemented by CDK12 (33).”
BackgroundResultCDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion
Tien, J. F., Mazloomian, A., Cheng, S.-W. G., Hughes, C. S., Chow, C. C. T., Canapi, L. T., Oloumi, A., Trigo-Gonzalez, G., Bashashati, A., Xu, J., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx187 · Cited by 163
CDK13 cooperates with CDK12 to control global RNA polymerase II processivity
Fan, Z., Devlin, J. R., Hogg, S. J., Doyle, M. A., Harrison, P. F., Todorovski, I., Cluse, L. A., Knight, D. A., Sandow, J. J., Gregory, G., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz5041 · Cited by 164
Self-citationCyclin Dependent Kinase 9 Inhibitors for Cancer Therapy: Miniperspective
Sonawane, Y. A., Taylor, M. A., Napoleon, J. V., Rana, S., Contreras, J. I., & Natarajan, A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00150 · Cited by 155
Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype
Olson, C. M., Liang, Y., Leggett, A., Park, W. D., Li, L., Mills, C. E., Elsarrag, S. Z., Ficarro, S. B., Zhang, T., Düster, R., et al. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.02.012 · Cited by 161
Self-citationStructural and functional analysis of the Cdk13/Cyclin K complex
Greifenberg, A. K., Hönig, D., Pilarova, K., Düster, R., Bartholomeeusen, K., Bösken, C. A., Anand, K., Blazek, D., & Geyer, M. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.025 · Cited by 157
“A similar mode of interaction has been found for Cdk12 and Cdk9 (Bösken et al., 2014; Baumli et al., 2012), suggesting this conformation a molecular feature of transcription elongation regulating kinases.”
BackgroundMethodSelf-citationDiscovery and resistance mechanism of a selective CDK12 degrader
Jiang, B., Gao, Y., Che, J., Lu, W., Kaltheuner, I. H., Dries, R., Kalocsay, M., Berberich, M. J., Jiang, J., You, I., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00765-y · Cited by 150
Self-citationCompensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism
Lu, H., Xue, Y., Yu, G. K., Arias, C., Lin, J., Fong, S., Faure, M., Weisburd, B., Ji, X., Mercier, A., et al. (2015) · eLife · doi:10.7554/elife.06535 · Cited by 149
“It is interesting to note that a similar finding has also been made with the pan-CDK inhibitor flavopiridol (Bosken et al., 2014).”
ResultHeptad-Specific Phosphorylation of RNA Polymerase II CTD
Schüller, R., Forné, I., Straub, T., Schreieck, A., Texier, Y., Shah, N., Decker, T.-M., Cramer, P., Imhof, A., & Eick, D. (2016) · Molecular Cell · doi:10.1016/j.molcel.2015.12.003 · Cited by 150
“Surprisingly, we did not detect in vivo changes in S5-P upon flavopiridol treatment, although it was reported that CDK9 phosphorylates S5 in vitro (Bösken et al., 2014; Czudnochowski et al., 2012), emphasizing a need for assessing the specificity of CTD kinases and phosphatases in vivo.”
BackgroundSelf-citationEkumi, K. M., Paculova, H., Lenasi, T., Pospichalova, V., Bösken, C. A., Rybarikova, J., Bryja, V., Geyer, M., Blazek, D., & Barboric, M. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv101 · Cited by 141
Self-citationCdk7: a kinase at the core of transcription and in the crosshairs of cancer drug discovery
Fisher, R. P. (2018) · Transcription · doi:10.1080/21541264.2018.1553483 · Cited by 158
“(Both Cdk12 and Cdk13 depend on phosphorylation for full activity [62,63], and have T-loop sequences that are nearly identical to each other and to that of Cdk9, a known Cdk7 target; it is likely, but not proven, that Cdk7 is also the activating kinase for these transcriptional CDKs.”
BackgroundSelf-citationSansó, M., Levin, R. S., Lipp, J. J., Wang, V. Y.-F., Greifenberg, A. K., Quezada, E. M., Ali, A., Ghosh, A., Larochelle, S., Rana, T. M., et al. (2016) · Genes & Development · doi:10.1101/gad.269589.115 · Cited by 139
“To test requirements for Cdk9, we treated cells with 50 µM DRB, 150 nM FP, or 150 nM 2-FP-FP for 1 or 4 h; these drugs caused approximately twofold to 10-fold increases in readthrough transcripts of all three genes (Fig.”
InfluentialSelf-citationThe RNA Polymerase II CTD: The Increasing Complexity of a Low-Complexity Protein Domain
Jerónimo, C., Collin, P., & Robert, F. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.02.006 · Cited by 151
CDK9 inhibitors define elongation checkpoints at both ends of RNA polymerase II–transcribed genes
Laitem, C., Zaborowska, J., Isa, N. F., Kufs, J., Dienstbier, M., & Murphy, S. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3000 · Cited by 133
“For example, CDK12 is Ser2 kinase that is recruited to the 3 ′ end of protein-coding genes and is inhibited by Flavopiridol in vitro 24-27 .”
CDK12: an emerging therapeutic target for cancer
Lui, G. Y. L., Grandori, C., & Kemp, C. J. (2018) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2018-205356 · Cited by 131
Targeting CDK9 for Anti-Cancer Therapeutics
Mandal, R., Becker, S., & Strebhardt, K. (2021) · Cancers · doi:10.3390/cancers13092181 · Cited by 139
“CDK9 Cyclins T1/T2a/T2b Positive regulation of transcription elongation [12] CDK10 Cyclin M Cell-cycle regulation and tumor suppressor [13,14] CDK12 Cyclin K Positive regulation of transcription elongation [15,16] CDK13 Cyclin K Positive regulation of transcription elongation [15,17] CDK14 Cyclin Y Regulation of cell-…”
BackgroundBaker, A., Gregory, G. P., Verbrugge, I., Kats, L. M., Hilton, J. J., Vidacs, E., Lee, E. M., Lock, R. B., Zuber, J. A., Shortt, J., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1070 · Cited by 124
“To further probe the effect of CDK inhibition on the survival of MLL-AF9;NRAS cells, we tested the effect of flavopiridol a small molecule inhibitor of CDKs 1, 2, 4, 6, 7, 9 and 12 (33, 34) and the more selective CDK 4/6 inhibitor palbociclib (35).”
CDK12 controls G1/S progression by regulating RNAPII processivity at core DNA replication genes
Chirackal Manavalan, A. P., Pilarova, K., Kluge, M., Bartholomeeusen, K., Rajecky, M., Oppelt, J., Khirsariya, P., Paruch, K., Krejci, L., Friedel, C. C., et al. (2019) · EMBO reports · doi:10.15252/embr.201847592 · Cited by 110
“CDK12 has been implicated in the transcription of a subset of genes via phosphorylation of RNAPII, particularly on Ser2 and Ser5 in the CTD [11 – 13, 16, 17 ].”
Wang, C., Wang, H., Lieftink, C., du Chatinier, A., Gao, D., Jin, G., Jin, H., Beijersbergen, R. L., Qin, W., & Bernards, R. (2020) · Gut · doi:10.1136/gutjnl-2019-318506 · Cited by 107
Human CDK12 and CDK13, multi-tasking CTD kinases for the new millenium
Greenleaf, A. L. (2019) · Transcription · doi:10.1080/21541264.2018.1535211 · Cited by 102
“” Pre-phosphorylation influences kinase specific activity: A very interesting observation of Geyer and co-workers is that in vitro both CDK12•CycK and CDK13•CycK are much more active toward CTD synthetic peptide repeats when Ser7 is prephosphorylated than when it is not [23,25].”
BackgroundInfluentialTherapeutic targeting of transcriptional cyclin-dependent kinases
Galbraith, M. D., Bender, H., & Espinosa, J. M. (2018) · Transcription · doi:10.1080/21541264.2018.1539615 · Cited by 111
“both S2 and S5, with the highest activity towards S5 on S7 pre-phosphorylated CTD [20].”
Dissecting the Pol II transcription cycle and derailing cancer with CDK inhibitors
Parua, P. K., & Fisher, R. P. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0563-4 · Cited by 119
Self-citationCDK9 keeps RNA polymerase II on track
Egloff, S. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03878-8 · Cited by 113
Tellier, M., Zaborowska, J., Caizzi, L., Mohammad, E., Velychko, T., Schwalb, B., Vicens, I. F., Blears, D., Nojima, T., Cramer, P., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa514 · Cited by 122
“In addition, CDK12 mainly phosphorylates Ser5 in vitro (15,16).”
Rimel, J. K., Poss, Z. C., Erickson, B., Maas, Z. L., Ebmeier, C. C., Johnson, J. L., Decker, T.-M., Yaron, T. M., Bradley, M. J., Hamman, K. B., et al. (2020) · Genes & Development · doi:10.1101/gad.341545.120 · Cited by 113
“CDK12:CCNK and CDK13:CCNK CDK12:CCNK complexes and CDK13:CCNK complexes were purified as described (Bösken et al. 2014; Greifenberg et al. 2016).”
MethodSelf-citationArchitecture of the Human and Yeast General Transcription and DNA Repair Factor TFIIH
Luo, J., Cimermančič, P., Viswanath, S., Ebmeier, C. C., Kim, B. K., Dehecq, M., Raman, V., Greenberg, C. H., Pellarin, R., Šali, A., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.07.016 · Cited by 98
“, 2010a) and a model of CDK7/Kin28-cyclin H/Ccl1 based on the CDK12-Cyclin K structure (Bösken et al., 2014).”
Niu, T., Li, K., Li, J., Zhou, Z., Hong, J.-E., Chen, X., Dong, X., He, Q., Cao, J., Yang, B., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114012 · Cited by 99
Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors
Kalra, S., Joshi, G., Munshi, A., & Kumar, R. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.08.071 · Cited by 98
The emerging roles of CDK12 in tumorigenesis
Paculová, H., & Kohoutek, J. (2017) · Cell Division · doi:10.1186/s13008-017-0033-x · Cited by 93
“The crystal structure of CDK12 was later described, opening new possibilities to study its function and its potential as a drug target and to develop specific CDK12 inhibitors [14].”
Booth, G. T., Parua, P. K., Sansó, M., Fisher, R. P., & Lis, J. T. (2018) · Nature Communications · doi:10.1038/s41467-018-03006-4 · Cited by 90
Self-citationCDK12: A Potent Target and Biomarker for Human Cancer Therapy
Liang, S., Hu, L., Wu, Z., Chen, Z., Liu, S., Xu, X., & Qian, A. (2020) · Cells · doi:10.3390/cells9061483 · Cited by 80
“Chirackal Manavalan et al. have found that the inhibition of CDK12 does not affect Ser2 phosphorylation level as well as global transcription but diminishes RNAP II processivity accompanied by transcript shortening of DNA replication genes, which is consistent with defective transcription elongation [9].”
BackgroundInfluentialActivation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors
Kalan, S., Amat, R., Schachter, M. M., Kwiatkowski, N. P., Abraham, B. J., Liang, Y., Zhang, T., Olson, C. M., Larochelle, S., Young, R. A., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.056 · Cited by 75
“…possibility, we treated CDK7as/as cells with increasing doses of 3-MB-PP1 in the absence or presence of flavopiridol (FP), a pan-CDK inhibitor that is most potent toward Cdk9 but that also inhibits Cdk12 at higher doses (Chao and Price, 2001; Bösken et al., 2014; Bartkowiak and Greenleaf, 2015).”
BackgroundSelf-citationLoyer, P., & Trembley, J. H. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.04.016 · Cited by 73
“Multiple in vitro and cellular evidence indicated that CDK12/Cyclin K and CDK13/Cyclin K complexes phosphorylated the CTD of RNAPII predominantly on S2 and S5 and with higher activities when S7 is pre-phosphorylated [45, 46].”
BackgroundIto, M., Tanaka, T., Toita, A., Uchiyama, N., Kokubo, H., Morishita, N., Klein, M. G., Zou, H., Murakami, M., Kondo, M., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00683 · Cited by 73
Cossa, G., Parua, P. K., Eilers, M., & Fisher, R. P. (2021) · Genes & Development · doi:10.1101/gad.348315.121 · Cited by 80
“2012), and substrate “priming”— the preference of certain CDKs for the CTD previously phosphorylated by a different CDK (Viladevall et al. 2009; Czudnochowski et al. 2012; St. Amour et al. 2012; Bösken et al. 2014; Greifenberg et al. 2016; Mayfield et al. 2019).”
BackgroundSelf-citationJiang, B., Jiang, J., Kaltheuner, I. H., Iniguez, A. B., Anand, K., Ferguson, F. M., Ficarro, S. B., Seong, B. K. A., Greifenberg, A. K., Dust, S., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113481 · Cited by 64
Self-citationStructure‐Based Design of Selective Noncovalent CDK12 Inhibitors
Johannes, J. W., Denz, C. R., Su, N., Wu, A. J., Impastato, A. C., Mlynarski, S. N., Varnes, J. G., Prince, D. B., Cidado, J. R., Gao, N., et al. (2017) · ChemMedChem · doi:10.1002/cmdc.201700695 · Cited by 62
The Promise and Current Status of CDK12/13 Inhibition for the Treatment of Cancer
Tadesse, S., Duckett, D. R., & Monastyrskyi, A. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0240 · Cited by 69
Abemaciclib is a potent inhibitor of DYRK1A and HIP kinases involved in transcriptional regulation
Kaltheuner, I. H., Anand, K., Moecking, J., Düster, R., Wang, J., Gray, N. S., & Geyer, M. (2021) · Nature Communications · doi:10.1038/s41467-021-26935-z · Cited by 55
Self-citationBartkowiak, B., & Greenleaf, A. L. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.612226 · Cited by 53
BRD4: a general regulator of transcription elongation
Altendorfer, E., Mochalova, Y., & Mayer, A. (2022) · Transcription · doi:10.1080/21541264.2022.2108302 · Cited by 62
Role and therapeutic potential of CDK12 in human cancers
Chilà, R., Guffanti, F., & Damia, G. L. M. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.09.003 · Cited by 54
Brägelmann, J., Dammert, M. A., Dietlein, F., Heuckmann, J. M., Choidas, A., Böhm, S., Richters, A., Basu, D., Tischler, V., Lorenz, C., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.08.082 · Cited by 60
“…complex after short-time in- hibitor treatment (Lu et al., 2015), it may be speculated that this effect is potentially due to involvement of other CDKs (e.g., CDK12 and/or CDK13) that were shown to be capable of phos- phorylating Ser2 of Pol II CTD (Bösken et al., 2014; Greifenberg et al., 2016).”
BackgroundStructure-based discovery of cyclin-dependent protein kinase inhibitors
Martin, M. P., Endicott, J., & Noble, M. E. M. (2017) · Essays in Biochemistry · doi:10.1042/ebc20170040 · Cited by 56
“Similar trapping of AMP-PNP in a closed state assisted by residues located within the C-terminal extension is observed in the structure of a CDK12-cyclin K-AMPPNP complex (PDBs 4NST, [71]; and 4CXA, [72]).”
CDK11 is required for transcription of replication-dependent histone genes
Gajdušková, P., Mozos, I. R. D. L., Rájecký, M., Hluchý, M., Ule, J., & Blažek, D. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0406-8 · Cited by 54
Houles, T., Boucher, J., Lavoie, G., MacLeod, G., Lin, S., Angers, S., & Roux, P. P. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01754-x · Cited by 49
“1B), a Pol II subunit and speci fi c substrate of CDK12 [26].”
BackgroundCell cycle regulation and hematologic malignancies
Dai, Y., Jin, F., Wu, W., & Kumar, S. K. (2019) · Blood Science · doi:10.1097/bs9.0000000000000009 · Cited by 48
Engineering an analog-sensitive CDK12 cell line using CRISPR/Cas
Bartkowiak, B., Yan, C., & Greenleaf, A. L. (2015) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2015.07.010 · Cited by 46
Cyclin‐dependent kinases: Masters of the eukaryotic universe
Pluta, A. J., Studniarek, C., Murphy, S., & Norbury, C. J. (2023) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1816 · Cited by 56
Li, X., Chatterjee, N., Spirohn, K., Boutros, M., & Bohmann, D. (2016) · Scientific Reports · doi:10.1038/srep21455 · Cited by 47
Taghizadeh, M. S., Taherishirazi, M., Niazi, A., Afsharifar, A., & Moghadam, A. A. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1327820 · Cited by 45
“Additionally, previous research has demonstrated the structural and sequence proximity between CDK12 and CDK9 (Bösken et al., 2014).”
BackgroundHeijkants, R. C., Willekens, K., Schoonderwoerd, M. J. A., Teunisse, A. F. A. S., Nieveen, M. C., Radaelli, E., Hawinkels, L., Marine, J., & Jochemsen, A. G. (2017) · Oncotarget · doi:10.18632/oncotarget.23485 · Cited by 46
“Flavopiridol strongly inhibits CDK9 activity, but also affects activities of CDK1, CDK2, CDK4, CDK6, CDK7 and CDK12 [24-27].”
CDK12: cellular functions and therapeutic potential of versatile player in cancer
Pilařová, K., Herudek, J., & Blažek, D. (2020) · NAR Cancer · doi:10.1093/narcan/zcaa003 · Cited by 50
Chen, H., Lin, G.-T., Huang, C.-K., & Fann, M. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.06.024 · Cited by 48
Modifications of RNA polymerase II CTD: Connections to the histone code and cellular function
Srivastava, R., & Ahn, S. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.07.008 · Cited by 45
CDK12 is hyperactivated and a synthetic-lethal target in BRAF-mutated melanoma
Houles, T., Lavoie, G., Nourreddine, S., Cheung, W., Vaillancourt-Jean, É., Guérin, C. M., Bouttier, M., Grondin, B., Lin, S., Saba-El-Leil, M. K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34179-8 · Cited by 40
Choi, S. H., Kim, S., & Jones, K. A. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0442-9 · Cited by 37
Dixon-Clarke, S. E., Elkins, J. M., Cheng, S.-W. G., Morin, G. B., & Bullock, A. N. (2015) · Scientific Reports · doi:10.1038/srep17122 · Cited by 38
Qiu, M., Yin, Z., Wang, H., Lei, L., Li, C., Cui, Y., Dai, R., Yang, P., Xiang, Y., Li, Q., et al. (2023) · Science Advances · doi:10.1126/sciadv.adf8698 · Cited by 35
CDK12: a potential therapeutic target in cancer
Emadi, F., Teo, T., Rahaman, M. H., & Wang, S. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.09.035 · Cited by 37
Transcriptional cyclin-dependent kinases: Potential drug targets in cancer therapy
Liu, Y., Fu, L., Wu, J., Liu, M., Wang, G., Liu, B., & Zhang, L. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114056 · Cited by 39
Chromatin modification by the RNA Polymerase II elongation complex
Tanny, J. C. (2014) · Transcription · doi:10.4161/21541264.2014.988093 · Cited by 36
Total RNA-seq to identify pharmacological effects on specific stages of mRNA synthesis
Boswell, S. A., Snavely, A. R., Landry, H. M., Churchman, L. S., Gray, J. M., & Springer, M. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2317 · Cited by 34
Discovery of Covalent CDK14 Inhibitors with Pan-TAIRE Family Specificity
Ferguson, F. M., Doctor, Z. M., Ficarro, S. B., Browne, C. M., Marto, J. A., Johnson, J. L., Yaron, T. M., Cantley, L. C., Kim, N. D., Sim, T., et al. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.02.015 · Cited by 34
“, 2012) and a homology model of CDK14 built using the structure of CDK12 (PDB: 5ACB)(Bosken et al., 2014).”
MethodTargeting CDKs in cancer therapy: advances in PROTACs and molecular glues
Marei, H. E. S., Bedair, K., Hasan, A., Al-Mansoori, L., Gaiba, A., Morrione, A., Cenciarelli, C., & Giordano, A. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00931-8 · Cited by 42
Isa, N. F., Bensaude, O., Aziz, N. N. C., & Murphy, S. (2021) · Vaccines · doi:10.3390/vaccines9101054 · Cited by 33
Cyclin-dependent kinases and rare developmental disorders
Colas, P. (2020) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-020-01472-y · Cited by 36
“due being located at the interaction interfaces with CDK13 [56] and CDK12 [58], the amino acid substitu-”
BackgroundInfluentialShi, Z., Zhao, Q., Lv, B., Qu, X., Han, X., Wang, H., Qiu, J., & Hua, K. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.399 · Cited by 39
CDK12 regulates co-transcriptional splicing and RNA turnover in human cells
Magnuson, B., Bedi, K., Narayanan, I. V., Bartkowiak, B., Blinkiewicz, H., Paulsen, M. T., Greenleaf, A. L., & Ljungman, M. E. (2022) · iScience · doi:10.1016/j.isci.2022.105030 · Cited by 35
“As a CTD-kinase, CDK12 acts downstream of CDK7 (Bosken et al., 2014) and CDK9 (Bartkowiak et al., 2010) during transcription elongation and phosphorylates Ser2, Ser5, and Thr4 of the CTD of RNAPII.”
BackgroundMethodChemical inhibitors of transcription-associated kinases
Clopper, K. C., & Taatjes, D. J. (2022) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2022.102186 · Cited by 34
A Tale of Chromatin and Transcription in 100 Structures
Cramer, P. (2014) · Cell · doi:10.1016/j.cell.2014.10.047 · Cited by 30
“Crystallography also revealed the mechanisms and the determinants for substrate specificity of CTD kinases (Baumli et al., 2012; Baumli et al., 2008; Bösken et al., 2014; Lolli et al., 2004; Schneider et al., 2011; Tahirov et al., 2010) and CTD phosphatases (Ghosh et al.”
Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors
Chou, J., Robinson, T. M., Egusa, E. A., Lodha, R., Zhang, M., Badura, M. L., Mikayelyan, M., Delavan, H. M., Swinderman, J. T., Wilson, C., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3785 · Cited by 32
Matrone, G., Wilson, K. S., Maqsood, S., Mullins, J. J., Tucker, C. S., & Denvir, M. A. (2015) · Journal of Cell Science · doi:10.1242/jcs.175018 · Cited by 28
“C), as Jo u rn al o f Ce ll Sc ie n ce predicted because of its known pharmacological action (Chao et al., 2000; Bosken et al., 2014).”
BackgroundInfluentialChatterboxes: the structural and functional diversity of cyclins
Tatum, N. J., & Endicott, J. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.04.021 · Cited by 31
Current progress and novel strategies that target CDK12 for drug discovery
Lei, P., Zhang, J., Liao, P., Ren, C., Wang, J., & Wang, D. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114603 · Cited by 27
Structural basis of Cdk7 activation by dual T-loop phosphorylation
Düster, R., Anand, K., Binder, S. C., Schmitz, M., Gatterdam, K., Fisher, R. P., & Geyer, M. (2024) · Nature Communications · doi:10.1038/s41467-024-50891-z · Cited by 26
Self-citationMann, M. W., Roberts, D. S., Zhu, Y., Li, Y., Zhou, J., Ge, Y., & Brasier, A. R. (2021) · Viruses · doi:10.3390/v13030454 · Cited by 23
Functional characterization of the human Cdk10/Cyclin Q complex
Düster, R., Ji, Y., Pan, K., Urlaub, H., & Geyer, M. (2022) · Open Biology · doi:10.1098/rsob.210381 · Cited by 22
Self-citationEmerging approaches to CDK inhibitor development, a structural perspective
Hope, I., Endicott, J., & Watt, J. E. (2022) · RSC Chemical Biology · doi:10.1039/d2cb00201a · Cited by 24
A combinatorial view of old and new RNA polymerase II modifications
Lyons, D. E., McMahon, S., & Ott, M. (2020) · Transcription · doi:10.1080/21541264.2020.1762468 · Cited by 25
“[187] Bosken CA, Farnung L, Hintermair C, et al.”
BackgroundKetley, A., Wojciechowska, M., Ghidelli, S., Bamborough, P., Ghosh, T. K., López-Morató, M., Sedehizadeh, S., Malik, N. A., Tang, Z., Powalowska, P. K., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz2415 · Cited by 28
“CDK12 is a transcription elongation–associated C-terminal repeat domain (CTD) kinase, which has been shown to regulate phosphorylation of serine-2 in the C-terminal domain of RNA Pol II, a step required for productive elongation of transcripts, rather than being involved in the initiation of transcription (44, 47).”
BackgroundBiswas, R., Gao, S., Cultraro, C. M., Maity, T. K., Venugopalan, A. K., Abdullaev, Z., Shaytan, A. К., Carter, C. A., Thomas, A., Rajan, A., et al. (2016) · Molecular Case Studies · doi:10.1101/mcs.a001263 · Cited by 22
“CDK12 harboring a point mutation within its DFG motif (D877N) has been identified in a cholangiocarcinoma patient sample from TCGA, and a CDK12 D877N expression construct has been used as a kinase dead control in various studies (Bosken et al. 2014).”
(2025) · doi:10.1016/j.molcel.2025.04.012 · Cited by 21
Zhang, X., Nguyen, K. D. P., Rudnick, P. A., Roper, N., Kawaler, E. A., Maity, T. K., Awasthi, S., Gao, S., Biswas, R., Venugopalan, A. K., et al. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra118.001266 · Cited by 20
“Further, this CDK12-D877N mutation has been used as a kinase dead control in various functional studies (18).”
MethodThe reversible inhibitor SR-4835 binds Cdk12/cyclin K in a noncanonical G-loop conformation
Schmitz, M., Kaltheuner, I. H., Anand, K., Düster, R., Moecking, J., Monastyrskyi, A., Duckett, D. R., Roush, W. R., & Geyer, M. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105501 · Cited by 20
Self-citation
Metadata
- Authors
- Bösken, C. A., Farnung, L., Hintermair, C., Merzel Schachter, M., Vogel-Bachmayr, K., Blazek, D., Anand, K., Fisher, R. P., Eick, D., & Geyer, M.
- Affiliations
- Center of Advanced European Studies and Research (DE)
- Max Planck Institute of Molecular Physiology (DE)
- Center for Integrated Protein Science Munich (DE)
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- Geyer, Matthias
- Venue
- Nature Communications
- Published
- 2014-03-24
- Volume
- 5
- Issue
- 1
- Pages
- 3505-3505
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC3973122
- OpenAlex
- W2074045994
- Semantic Scholar
- 7f2f1f4958b1ced0a261be63f6b87c33e72321b5
- Cited by
- 191
- References
- 60
- Citations by year
- 2026: 15 · 2025: 21 · 2024: 16 · 2023: 13 · 2022: 18 · 2021: 19 · 2020: 21 · 2019: 12 · 2018: 7 · 2017: 14 · 2016: 13 · 2015: 13 · 2014: 9
- FWCI
- 6.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DORA PSI (Paul Scherrer Institute) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- Max Planck Digital Library (submittedVersion)
- Max Planck Digital Library (submittedVersion, other-oa)
- Site cant be reached (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion, other-oa)
- Funders
- Deutsche Forschungsgemeinschaft (SFB 684, SFB/TR 5)
- Grantová Agentura České Republiky (CZ.1.05/1.1.00/02.0068, GA14-09979S)
- Central European Institute of Technology (CZ.1.05/1.1.00/02.0068., CZ.1.05/1.1.00/02)
- International Max Planck Research School for Advanced Methods in Process and Systems Engineering
- National Institutes of Health
- National Cancer Institute (T32-CA78207, T32CA078207)
- National Institute of General Medical Sciences (GM104291, R01GM104291)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- CDK12, cyclin K, cyclin-dependent kinases, RNA polymerase II C-terminal domain, CTD phosphorylation, substrate specificity, crystal structure, flavopiridol, T-loop phosphorylation, CDK-activating kinase, transcription elongation
- MeSH terms
- Crystallization, Enzyme-Linked Immunosorbent Assay, HeLa Cells, Humans, Models, Molecular, Protein Conformation, Mass Spectrometry, Substrate Specificity, Blotting, Western, Cyclins, Cyclin-Dependent Kinases, Multiprotein Complexes, Immunoprecipitation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.